• Molecular NameSitagliptin
  • SynonymMK-0431; Sitagliptan; sitagliptin; Sitagliptin phosphate
  • Weight407.318
  • Drugbank_IDDB01261
  • ACS_NO486460-32-6
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.45
  • pkaN/A
  • LogD (pH=7, predicted)-0.15
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-4.12
  • LogSw (predicted, AB/LogsW2.0)0.07
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA77.04
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, Sitagliptin being the only second generation DPP-4 inhibitor currently available in the USA.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed following oral administration, with an absolute bioavailability of 87%.
  • Caco_2N/A
  • Bioavailability87.0
  • Protein binding38.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP3A4- and CYP2C8-mediated)
  • Half life8~14 h
  • ExcretionRenal (80%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityHypoglycemia, nasopharyngitis, headache, upper respiratory tract infection.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A